Abstracts by keywords: new drugs
Around 1.4 million people with dementia live in Germany today (around 35 million worldwide). According to forecasts, this number will double to around 3 million people by 2050 (115 million worldwide). On this basis, an increase of 40,000 new cases per year is predicted. One reason for this development is demographic change, which describes an increasingly aging population [1, see Fig. 1]. Age is the greatest risk factor for dementia because the likelihood of the disease increases sharply with age. This is z. For example, for 65-74 year olds it is only 1.7%, for 75-84 year olds it is 11% and increases exponentially to 30% for 84 year olds [2]. Overall, it can be said that the economic relevance of dementia will increase. One consequence of dementia is the patient's early need for care and the depression that is often associated with this disease. Depending on the severity of the disease and the resulting care effort, the costs are around 15,000-42,000 euros per patient per year [3]. Most patients today are still cared for at home with the help of relatives. The resulting costs are not yet factored into the above. As a result, the actual costs of caring for dementia patients are even higher. Furthermore, in the future there will be fewer and fewer younger people who can take on this care. One way to limit the predicted amount of care would be to provide appropriate, high-quality therapy. The aim of the present study was to analyze the care of dementia patients with galantamine based on our insurance data. <<
31.03.2016
Numerous medications are available to treat patients with type 2 diabetes mellitus (T2DM). Metformin and sulfonylureas have been in use for decades and can be used either as monotherapy or as part of combination therapies [12–14]. Since the mid-2000s, numerous new drugs have appeared on the market for the treatment of T2DM that cause fewer side effects than metformin and sulfonylureas: inhibitors of dipeptidyl peptidase 4 (DPP4), glucagon-like peptide 1 (GLP-1) receptor agonists and inhibitors the sodium/glucose cotransporter 2 (SGLT2). Their use in Europe was approved by the European Medicines Agency (EMA) in 2007, 2009 and 2013, respectively [15–17]. While DPP-4 inhibitors and GLP-1 stimulate the release of insulin and inhibit that of glucagon, the SGLT2 inhibitors influence the renal reabsorption of glucose [18–20]. Although these three drug classes have different mechanisms of action, they all prevent hyperglycemia and regulate HbA1c in patients with T2DM [18,19,21]. Although such drugs have already proven their effectiveness, the success of these therapies depends not only on the drugs themselves, but also on compliance [22], nutrition [23], management and treatment strategies [24,25]. The aim of this study was therefore to analyze the changes in a German T2DM population before (2006) and after (2010, 2014) the introduction of these new drugs in order to gain a better understanding of their effects.